Krystal Biotech (NASDAQ:KRYS) PT Raised to $220.00 at Stifel Nicolaus

Krystal Biotech (NASDAQ:KRYS) had its price target hoisted by Stifel Nicolaus from $204.00 to $220.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other research analysts also recently commented on the company. Cantor Fitzgerald reaffirmed an overweight rating on shares of Krystal Biotech in a research note on Thursday, August 29th. Chardan Capital raised their price objective on Krystal Biotech from $153.00 to $208.00 and gave the stock a buy rating in a research note on Monday, August 5th. HC Wainwright lifted their target price on Krystal Biotech from $200.00 to $221.00 and gave the company a buy rating in a research note on Wednesday, August 28th. William Blair raised Krystal Biotech to a strong-buy rating in a research note on Friday, August 30th. Finally, Evercore ISI lifted their target price on Krystal Biotech from $201.00 to $206.00 and gave the company an outperform rating in a research note on Monday, August 12th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Krystal Biotech has an average rating of Buy and an average target price of $196.75.

Krystal Biotech Stock Up 3.0 %

NASDAQ KRYS opened at $201.58 on Wednesday. The stock’s 50-day moving average price is $196.03 and its 200-day moving average price is $178.58. Krystal Biotech has a 52 week low of $93.95 and a 52 week high of $219.34. The company has a market capitalization of $5.79 billion, a P/E ratio of 107.80 and a beta of 0.82.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, August 5th. The company reported $0.53 EPS for the quarter, topping the consensus estimate of $0.50 by $0.03. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. The firm had revenue of $70.28 million for the quarter, compared to the consensus estimate of $65.27 million. During the same quarter last year, the company earned ($1.25) earnings per share. The business’s revenue for the quarter was up 70283900.0% compared to the same quarter last year. Research analysts anticipate that Krystal Biotech will post 3.13 EPS for the current year.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the transaction, the insider now owns 1,500,882 shares in the company, valued at approximately $296,814,424.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 14.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Krystal Biotech

Several institutional investors have recently added to or reduced their stakes in KRYS. Charles Schwab Investment Management Inc. boosted its holdings in shares of Krystal Biotech by 2.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 185,038 shares of the company’s stock worth $22,956,000 after purchasing an additional 5,258 shares during the period. BNP Paribas Financial Markets increased its position in shares of Krystal Biotech by 34.7% during the 4th quarter. BNP Paribas Financial Markets now owns 39,072 shares of the company’s stock valued at $4,847,000 after purchasing an additional 10,057 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Krystal Biotech by 5.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 550,806 shares of the company’s stock valued at $68,337,000 after purchasing an additional 30,169 shares during the last quarter. Fiera Capital Corp bought a new position in shares of Krystal Biotech during the 4th quarter valued at approximately $1,973,000. Finally, Quest Partners LLC bought a new position in shares of Krystal Biotech during the 4th quarter valued at approximately $127,000. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).